Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies

Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain cancer treatments, especially targeted chemotherapy drugs, might affect the heart. The researchers want to closely watch cancer patients receiving these treatments to catch any early signs of heart problems. They will do this by using heart tests like ECGs (which check heart rhythm), echocardiograms (which make pictures of the heart), and blood tests that look for heart stress or damage. The goal is to create a way to predict which patients might have serious heart issues during or after cancer treatment, so doctors can better protect their heart health. The study will also look at how these heart-related side effects and the monitoring process affect patients’ overall well-being and quality of life.

Adults with any type of confirmed cancer who are currently receiving or planning to receive chemotherapy, including targeted cancer drugs, may be eligible to join. To participate, patients need to be able to provide consent and agree to regular heart check-ups and provide blood samples. People who have had recent severe heart or brain problems or who don’t complete their planned chemotherapy at the study center won’t be eligible. If you join, you can expect regular heart monitoring before, during, and after your cancer treatment to help spot any early heart concerns. This study aims to help improve care for cancer patients by understanding and preventing heart-related side effects from cancer therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Adults (age \> 18 years) with a pathologically confirmed malignant tumor (any type of cancer); 2.Currently receiving or planning to receive chemotherapy (including regimens containing molecular targeted drugs) as adjuvant treatment for cancer; 3.Willing and able to participate in the study with provision of informed consent, and agreeable to provide required clinical data and biological samples.
• • -
• Exclusion Criteria:
• • 1. Incomplete basic patient information or medical records (missing key data necessary for the study);
• • 2. Failure to complete the full course of planned chemotherapy at the study center (e.g., patient did not adhere to or finish all cycles of adjuvant chemotherapy at our institution);
• • 3. History of severe acute cardiovascular or cerebrovascular events within 6 months prior to enrollment, including acute heart failure, acute myocardial infarction, acute intracerebral hemorrhage (stroke), malignant arrhythmia, or New York Heart Association (NYHA) Class IV/V heart failure;
• • 4. Missing essential pre- or post-chemotherapy evaluations: patients who did not undergo complete baseline or end-of-treatment assessments (such as blood routine, hepatic/renal function, coagulation profile, cardiac enzymes (troponin T), NT-proBNP (or BNP), 12-lead ECG, and echocardiogram)